EDAP Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer. This reimbursement took effect on July 1, 2023. Meeting to Showcase EDAP’s Focal One® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer EDAP TMS SA, a global leader in robotic energy-based therapies, today announced that the Company will host a webcast that will feature a live procedure broadcast of its Focal One HIFU as a potential treatment for ablating cancer tissue in patients who are diagnosed with prostate cancer. The webcast is scheduled for Tuesday, April 18th at 12:00 p.m. PDT (3:00 p.m. EDT). EDAP Announces Leadership Succession Plan to Develop Global Group Strategy EDAP TMS SA, a global leader in robotic energy-based therapies, announced today unaudited financial results for the fourth quarter and full-year 2022 EDAP TMS SA, a global leader in robotic energy-based therapies, today announced preliminary unaudited fourth quarter and full year 2022 revenue and other financial highlights. EDAP TMS SA, the global leader in robotic energy-based therapies, today announced positive clinical results from the Endo-HIFU-R1 Phase 2 study evaluating the safety of therapeutic high-Intensity focused ultrasound (HIFU) for the treatment of rectal endometriosis. Results from the study were presented by study coordinator, Pr. Gil Dubernard of Croix Rousse University Hospital (Lyon, France), on Friday, January 27, at the Paris Santé Femmes French Congress1 (Lille, France). EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Proposed Rule for CY23 EDAP’s Focal One® HIFU to be Showcased at Two Major Robotics & Urology International Congresses
Mar 4, 2024
EDAP Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis
Jul 26, 2023
EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer
Apr 21, 2023
EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)
Apr 11, 2023
EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience
Mar 30, 2023
EDAP Announces Leadership Succession Plan to Develop Global Group Strategy
Mar 30, 2023
EDAP Reports Record Fourth Quarter and Full-Year 2022 Results
Feb 14, 2023
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2022 Revenue
Jan 31, 2023
EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic for the Treatment of Rectal Endometriosis
Jul 18, 2022
EDAP Announces Focal One® HIFU Reimbursement Raised
Jun 24, 2022
EDAP’s Focal One® HIFU to be Showcased at Two Major Robotics & Urology International Congresses